证券代码：300181 证券简称：佐力药业 公告编号：2023-048 浙江佐力药业股份有限公司 关于使用部分闲置募集资金进行现金管理的进展 公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"或"本公司"）于 2023 年 3 月 14 日召开了第七届董事会第十四次（临时）会议、第七届监事会第十二次 （临时）会议，审议通过了《关于使用部分闲置募集资金和闲置自有资金进行现 金管理的议案》，同意公司使用额度不超过人民币 30,000 万元（含本数）的闲 置募集资金和不超过人民币 20,000 万元（含本数）的闲置自有资金进行现金管 理，现金管理有效期自董事会审议通过之日起 12 个月内有效，在上述额度及有 效期内，资金可以循环滚动使用。同时，授权董事长在额度范围内行使该项投资 决策权并签署相关文件，公司财务部门组织实施。该授权自董事会审议通过之日 起 12 个月内有效。上述具体内容详见公司于 2023 年 3 月 14 日在巨潮资讯网披 露的《关于使用部分闲置募集资金和闲置自有资金进行现金管理的公告》（公告 编号：2 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-046 浙江佐力药业股份有限公司 二、对外担保进展情况 鉴于公司与中信银行西宁分行于 2023 年 1 月 9 日签署的《最高额保证合同》 已到期且执行完毕。近日，公司与中信银行西宁分行签署了《最高额保证合同》， 同意公司为珠峰药业向中信银行西宁分行申请2,000万元人民币的授信额度（敞口） 提供连带责任保证担保。上述担保属于已审议通过的担保事项范围，无需再次提交 董事会审议。 三、担保协议的主要内容 1、保证人：浙江佐力药业股份有限公司 2、债权人：中信银行股份有限公司西宁分行 关于为控股子公司向银行申请授信额度提供担保的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江佐力药业股份有限公司（以下简称"公司"）于 2022 年 10 月 24 日召开 了第七届董事会第十二次会议、第七届监事会第十次会议，审议通过了《关于调整 控股子公司担保额度及期限的议案》，同意公司对青海珠峰冬虫夏草药业有限公司 （以下简称"珠峰药业"）向银行申请授信担保额度及期限做出相应调整，其 ...

证券代码：300181 证券简称：佐力药业 公告编号：2023-047 浙江佐力药业股份有限公司 关于公司及控股子公司参与江苏省第四轮药品集中 带量采购拟中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，浙江佐力药业股份有限公司（以下简称"公司"）及控股子公司青海 珠峰冬虫夏草药业有限公司（以下简称"珠峰药业"）参与了江苏省第四轮药品 集中带量采购工作，根据江苏省医疗保障局于 2023 年 11 月 9 日发布的《江苏 省第四轮药品集中带量采购公告（四）》显示，公司产品乌灵胶囊、珠峰药业产 品百令片拟中选本次集中带量采购，现将相关拟中选情况公告如下： 注：上述产品的采购数量以江苏省医疗保障局发布的最终数据及公司和控股子公司后续 签订的相关采购协议为准。根据江苏省医疗保障局发布的《江苏省第四轮药品集中带量采购 1 产品名称 适应症 剂型 规格 转换 比 包装 单位 包装 材料 备注 乌灵胶囊 补肾健脑，养心安 神。用于心肾不 交 所 致 的 失眠、健 忘、心悸心烦、神疲 乏力、腰膝酸软、头 晕耳鸣、少气懒言、 脉细或沉无力；神经 衰弱见上述证候者 ...

证券代码：300181 证券简称：佐力药业 编号：2023-011 浙江佐力药业股份有限公司 投资者关系活动记录表 投资者关系活 □特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动  现场参观  其他 （线上会议） 参与单位名称 2023 年 10月31 日：银华基金：吴颖；猎户星投研：梁挺； 及人员姓名 杭州象树资产：相迎；宁波量力资本：林杰、叶倩羲；华创 证券：董致君；深圳望正资产：高敏。 2023 年 11 月 1 日：东吴医药：朱国广；富国基金：于洋、 张啸伟、赵伟、韩雪、李淼、吴畏。 时间 2023 年 10月31 日10:30-11:30 2023 年 11月1 日 9:30-10:00 地点 现场会议、线上会议 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 453,488,563.91, representing a 0.90% increase year-over-year, while the year-to-date revenue reached CNY 1,464,947,132.50, up 8.97% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was CNY 89,203,600.05, a 29.14% increase year-over-year, and the year-to-date net profit was CNY 286,865,191.49, reflecting a 40.65% growth[4] - The basic earnings per share for Q3 2023 was CNY 0.1272, up 12.07% year-over-year, with a year-to-date diluted earnings per share of CNY 0.4090, an increase of 22.05%[4] - Total operating revenue for the period reached CNY 1,464,947,132.50, an increase of 8.95% compared to CNY 1,344,402,602.13 in the previous period[18] - Net profit for the period was CNY 292,583,698.54, representing a 36.3% increase from CNY 214,596,952.02 in the previous period[20] - Basic and diluted earnings per share increased to CNY 0.4090 from CNY 0.3351, reflecting a growth of approximately 22%[21] Assets and Liabilities - The company's total assets at the end of Q3 2023 were CNY 3,543,470,789.72, a decrease of 2.63% from the end of the previous year[4] - The company's total assets decreased to CNY 3,543,470,789.72 from CNY 3,639,117,963.07, indicating a reduction in asset base[17] - Total liabilities decreased to CNY 830,182,267.56 from CNY 879,192,754.90, showing a decline in overall liabilities[17] - The total number of common shareholders was 40,247, with the largest shareholder holding 18.52% of the shares[13] - The total equity attributable to shareholders of the parent company was CNY 2,667,380,677.87, slightly down from CNY 2,703,749,664.26, indicating a minor decrease in shareholder equity[17] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 223,951,981.61, showing a 15.50% increase compared to the previous year[4] - The net cash inflow from operating activities was CNY 223.95 million, an increase of CNY 30.05 million or 15.50% year-on-year, primarily due to the growth in net profit and operating cash inflows[10] - Cash inflow from operating activities reached CNY 1,634,268,265.69, up from CNY 1,358,686,568.10, indicating a growth of about 20%[21] - The net cash flow from operating activities was CNY 223,951,981.61, compared to CNY 193,904,381.17 in the previous period, representing an increase of approximately 15.5%[21] - The net cash outflow from investing activities was CNY 115.15 million, an increase of CNY 52.45 million or 83.66% year-on-year, mainly due to a decrease in net cash inflow from investment products and an increase in long-term asset investments[10] - Cash outflow from investing activities totaled CNY 156,183,883.94, down from CNY 356,584,246.43, showing a reduction of about 56%[22] - The net cash flow from investing activities was -CNY 115,148,365.94, worsening from -CNY 62,695,018.67 in the previous period[22] - The net cash outflow from financing activities was CNY 170.68 million, an increase of CNY 4.61 million or 2.78% year-on-year, primarily due to increased dividend distributions and short-term borrowings[10] - The net cash flow from financing activities was -CNY 170,678,901.88, slightly worsening from -CNY 166,066,812.99 in the previous period[22] Investments and Projects - The company reported a significant increase in construction in progress, which rose to CNY 149,094,700, an increase of 91.01% due to ongoing investments in new projects[7] - The company plans to continue investing in the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project" and the "Innovative Pharmaceutical Industrialization Project" to enhance its market position[8] - Research and development expenses increased to CNY 58,183,284.31 from CNY 50,502,876.94, highlighting ongoing investment in innovation[18] Other Financial Metrics - The company's cash and cash equivalents were CNY 1,010.08 million, down from CNY 1,082.07 million at the beginning of the year[15] - Accounts receivable increased to CNY 461.29 million from CNY 452.84 million at the beginning of the year[15] - Inventory increased significantly to CNY 400.31 million from CNY 318.83 million at the beginning of the year[15] - The company reported a financial income of CNY 17,342,268.01, significantly higher than CNY 1,791,225.26 in the previous period, indicating improved financial management[18] - Other comprehensive income after tax was reported at CNY -121,960,107.00, compared to CNY -264,556,940.89, reflecting a reduction in losses from other comprehensive income[20] - The report for the third quarter was not audited, indicating that the figures are preliminary and subject to change[23]

Financial Performance - The company's revenue for Q3 2023 was ¥453,488,563.91, an increase of 0.90% compared to the same period last year, while year-to-date revenue reached ¥1,464,947,132.50, up 8.97% year-on-year [4]. - Net profit attributable to shareholders for Q3 2023 was ¥89,203,600.05, representing a 29.14% increase year-on-year, and year-to-date net profit was ¥286,865,191.49, up 40.65% [4]. - The basic earnings per share for Q3 2023 was ¥0.1272, a 12.07% increase compared to the same period last year, with year-to-date diluted earnings per share also at ¥0.4090, up 22.05% [4]. - Total operating revenue for the current period reached CNY 1,464,947,132.50, an increase of 8.95% compared to CNY 1,344,402,602.13 in the previous period [20]. - Net profit for the current period was CNY 292,583,698.54, representing a 36.24% increase from CNY 214,596,952.02 in the previous period [21]. - Earnings per share (EPS) increased to CNY 0.4090 from CNY 0.3351, marking a growth of 22.05% [22]. Assets and Liabilities - The company's total assets at the end of Q3 2023 were ¥3,543,470,789.72, a decrease of 2.63% from the end of the previous year [4]. - The company’s equity attributable to shareholders at the end of Q3 2023 was ¥2,667,380,677.87, a decrease of 1.35% from the end of the previous year [4]. - The total liabilities decreased to CNY 830,182,267.56 from CNY 879,192,754.90, a reduction of 5.57% [22]. - The total equity attributable to shareholders of the parent company was CNY 2,667,380,677.87, down from CNY 2,703,749,664.26, a decline of 1.34% [22]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥223,951,981.61, an increase of 15.50% compared to the same period last year [4]. - The net cash inflow from operating activities was CNY 223.95 million, an increase of CNY 30.05 million or 15.50% year-on-year [11]. - The net cash outflow from investing activities was CNY 115.15 million, an increase of CNY 52.45 million or 83.66% year-on-year, primarily due to reduced cash inflow from financial product investments and increased long-term asset investments [11]. - The net cash outflow from financing activities was CNY 170.68 million, an increase of CNY 4.61 million or 2.78% year-on-year, mainly due to increased dividend distribution and short-term borrowings [11]. - The cash inflow from operating activities totaled CNY 1,634,268,265.69, compared to CNY 1,358,686,568.10, indicating an increase of 20.24% [23]. - The cash outflow for debt repayment was CNY 204,830,690.32, a decrease of 7.7% from CNY 222,000,000.00 in the same quarter last year [24]. Investments and Expenses - The company reported a significant increase in construction in progress, which rose to ¥149,094,700, an increase of 91.01% due to ongoing investments in smart traditional Chinese medicine production base and new pharmaceutical industrialization projects [8]. - Research and development expenses rose to CNY 58,183,284.31, up from CNY 50,502,876.94, reflecting a growth of 15.24% [20]. - The company experienced a 46.13% decline in revenue from formula granules, totaling ¥27,513,000, due to ongoing registration processes with national and provincial standards [9]. - The company recorded a significant increase in interest income, reaching CNY 17,342,268.01 compared to CNY 1,791,225.26 in the previous period [21]. Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 40,247 [13]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, with 129,890,463 shares pledged [13]. Other Information - The company did not undergo an audit for the Q3 report [25]. - The report was issued by the board of directors on October 20, 2023 [26].

证券代码：300181 证券简称：佐力药业 公告编号：2023-041 浙江佐力药业股份有限公司 关于控股子公司参与上海市中成药带量采购拟中选的 公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，浙江佐力药业股份有限公司（以下简称"公司"）控股子公司青海珠 峰冬虫夏草药业有限公司（以下简称"珠峰药业"）参加了上海市中成药带量采 购的投标工作，根据上海阳光医药采购网于 2023 年 8 月 28 日发布的《上海市中 成药带量采购拟中选结果公示》（沪药事药品〔2023）87 号〕显示，公司控股子 公司珠峰药业产品百令片拟中选本次带量采购，现将相关情况公告如下： 注：上述品种的拟中选价格以上海阳光医药采购网发布的最终数据为准。根据上海阳光 医药采购网于 2023 年 8 月 15 日发布的《关于开展本市中成药带量采购有关工作的通知》 （沪药事药品〔2023）84 号〕的规定："采购周期为两年，视情况可延长。采购周期内采购 协议每年一签，续签采购协议时，约定采购量原则上不少于上一年。采购周期内医疗机构应 优先使用本次药品集中采购中选药品，并确保完成约定采购 ...

本次变更保荐代表人后，公司 2022 年度向特定对象发行股票的保荐代表人 为崔敏捷女士和黄世瑾先生，持续督导期至 2024 年 12 月 31 日止。公司董事会 对持续督导保荐代表人刘源先生和刘伟石先生在公司持续督导期所做出的努力 表示衷心感谢！ 特此公告。 浙江佐力药业股份有限公司 证券代码：300181 证券简称：佐力药业 公告编号：2023-040 浙江佐力药业股份有限公司 关于变更保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于近日收到保荐机构国金 证券股份有限公司（以下简称"国金证券"）出具的《关于更换浙江佐力药业股 份有限公司持续督导保荐代表人的函》，国金证券为公司 2022 年度向特定对象 发行股票的保荐机构，原委派刘源先生和刘伟石先生为公司持续督导工作的保荐 代表人。现为更好地开展后续的持续督导工作，国金证券决定委派保荐代表人崔 敏捷女士和黄世瑾先生（简历详见附件）接替刘源先生和刘伟石先生继续履行公 司持续督导期间的工作。 黄世瑾先生：国金证券股份有限公司上海证券承销保荐分公司保荐 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥1,011,458,568.59, representing a 13.02% increase compared to ¥894,948,098.95 in the same period last year[19]. - Net profit attributable to shareholders was ¥197,661,591.44, a significant increase of 46.54% from ¥134,887,213.05 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥193,733,354.17, up 48.41% from ¥130,543,414.51 year-on-year[19]. - Basic earnings per share increased by 27.17% to ¥0.2818 from ¥0.2216 in the same period last year[19]. - The total profit reached 228.71 million yuan, up 42.65% compared to the same period last year[41]. - The company reported a significant increase in construction in progress, rising to ¥110,832,339.21 from ¥78,057,355.85, an increase of approximately 41.9%[164]. - The company’s total comprehensive income for the first half of 2023 was CNY 107,094,418.16, compared to a loss of CNY 70,048,946.29 in the same period of 2022[172]. - The company reported a total revenue from sales of goods and services of CNY 1,017,734,404.34, up from CNY 846,735,398.62 in the same period last year, marking an increase of approximately 20.2%[177]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,548,700,558.22, a decrease of 2.48% from ¥3,639,117,963.07 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 3.71% to ¥2,603,411,549.83 from ¥2,703,749,664.26 at the end of the previous year[19]. - Total liabilities increased to ¥898,941,209.44 from ¥879,192,754.90, reflecting a rise of about 2.0%[165]. - Current liabilities totaled ¥813,081,074.86, up from ¥754,939,997.44, indicating an increase of approximately 7.6%[165]. - The company's total equity as of June 30, 2023, is 70,138.7335 million, with a registered capital of 70,138.7335 million[197]. Cash Flow - The net cash flow from operating activities was ¥123,191,852.79, down 6.83% from ¥132,222,204.29 in the same period last year[19]. - The company's investment activities generated a net cash flow of -¥92,967,216.55, a significant decrease of 92.85% compared to -¥48,207,873.28 in the same period last year, mainly due to the net redemption of ¥50 million in financial products[51]. - Cash and cash equivalents at the end of the period totaled CNY 945,716,264.17, down from CNY 1,062,579,204.42 at the beginning of the year, reflecting a decrease of approximately 11%[178]. Research and Development - Research and development expenses increased by 34.84% to ¥43,115,918.05, primarily due to investments in the clinical application expansion of Wuling capsules in mental and physical health fields and the development of the indication for IBS-D for Pukapofei tablets[51]. - The R&D expenditure for the first half of 2023 was 600 million yuan, accounting for 8.3% of total revenue[186]. - The company is focusing on research and development of new technologies to drive innovation and growth in the upcoming quarters[190]. Market Position and Strategy - The company is positioned as a leader in the pharmaceutical field of medicinal fungi, focusing on innovation and development[30]. - The company continues to strengthen market expansion, particularly in core products like Wuling Capsules and Lingze Tablets, which have shown good sales growth[41]. - The company plans to enhance its market competitiveness by expanding into new channels such as "Internet+" and e-commerce[84]. - The company is actively exploring new sales channels, including e-commerce platforms like Alibaba Health and JD Medicine, to enhance product accessibility[41]. Risks and Compliance - The company has outlined its commitment to ethical practices in its share issuance and trading activities, enhancing its reputation in the market[106]. - The company faces risks from industry policy changes and will adjust its business strategies accordingly[84]. - The company has recognized significant goodwill from acquisitions, which poses a risk of impairment if future earnings do not meet expectations[86]. Shareholder Information - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, totaling 129,890,463 shares, with 90,000,000 shares pledged[149]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[153]. - The total number of shareholders at the end of the reporting period was 34,061[149]. Community and Environmental Responsibility - The company has been actively involved in community welfare activities, including support for the elderly and donations to disabled individuals[104]. - The company emphasizes environmental protection and has been operating under the ISO 14001 environmental management system for nearly 20 years[104]. - The company focuses on sustainable supply chain development, incorporating social responsibility performance into supplier assessments[103].

证券代码：300181 证券简称：佐力药业 公告编号：2023-035 1、审议通过《关于<公司 2023 年半年度报告及其摘要>的议案》 经审核，监事会认为董事会编制和审核公司《2023 年半年度报告及其摘要》 的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地 反映了公司 2023 年半年度经营的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 《2023 年半年度报告》及《2023 年半年度报告摘要》具体内容详见公司同 日披露在中国证监会指定创业板信息披露网站上的相关公告。《2023 年半年度报 告披露提示性公告》将同时刊登在公司指定信息披露报刊证券时报、中国证券报、 上海证券报、证券日报。 浙江佐力药业股份有限公司 第七届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第七届监事会第十五次会 议于2023年8月7日在公司会议室以现场表决的方式召开。会议通知于2023年7 月27日以专人送达、电话、传真及电子邮件等相结合方式送达各监 ...